David Aguilera-Alonso

David Aguilera-Alonso

Auto-generated profile, based on publicly available information

David Aguilera-Alonso

Innovación e investigación en Pediatría Global, Instituto de Investigación 12 de Octubre (imas12), Fundación de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
DADavid Aguilera-Alonso
David Aguilera-Alonso
LELuis Escosa-García
Luis Escosa-García
JSJesús Saavedra-Lozano
Jesús Saavedra-Lozano
ECEmilia Cercenado
Emilia Cercenado
FBFernando Baquero-Artigao
Fernando Baquero-Artigao
Carbapenem-resistant organisms (CRO) are a major global public health threat. Enterobacterales hydrolyze almost all β-lactams through carbapenemase production. Infections caused by CRO are challenging to treat due to the limited number of antimicrobial options. This leads to significant morbidity and mortality. Over the last few years, several new antibiotics effective against CRO have been approved.

2 September 2022 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
DADavid Aguilera-Alonso
David Aguilera-Alonso
JAJosé Antonio Alonso-Cadenas
José Antonio Alonso-Cadenas
MRMarc Roguera-Sopena
Marc Roguera-Sopena
NLNicola Lorusso
Nicola Lorusso
LMLucía García San Miguel
Lucía García San Miguel
CCCristina Calvo
Cristina Calvo

4 May 2023 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ECElvira Cobo-Vázquez
Elvira Cobo-Vázquez
DADavid Aguilera-Alonso
David Aguilera-Alonso
TCTania Carbayo
Tania Carbayo
LFLucía M Figueroa-Ospina
Lucía M Figueroa-Ospina
FSFrancisco Sanz-Santaeufemia
Francisco Sanz-Santaeufemia
JSJesús Saavedra-Lozano
Jesús Saavedra-Lozano

8 April 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
ATAlfredo Tagarro
Alfredo Tagarro
OCOlga-Nerea Coya
Olga-Nerea Coya
APAna Pérez-Villena
Ana Pérez-Villena
BIBeatriz Iglesias
Beatriz Iglesias
ANAdriana Navas
Adriana Navas
CMCinta Moraleda
Cinta Moraleda

30 April 2021 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
DADavid Aguilera-Alonso
David Aguilera-Alonso
SMSara Murias
Sara Murias
AAAmelia Martinez de Azagra
Amelia Martinez de Azagra
ASAntoni Soriano-Arandes
Antoni Soriano-Arandes
MPMarta Pareja
Marta Pareja
Cristina CalvoCristina Calvo
Cristina Calvo
Knowledge of thrombosis in children with SARS-CoV-2 is scarce. In this multicentre national cohort of children with SARS-CoV-2 involving 49 hospitals, 4 patients out of 537 infected children developed a thrombotic complication (prevalence of 0.7% (95% CI: 0.2% to 1.9%) out of the global cohort and 1.1% (95% CI: 0.3% to 2.8%) out of the hospitalised patients). We describe their characteristics and review other published paediatric cases. Three out of the four patients were adolescent girls, and only two cases had significant thrombotic risk factors. In this paediatric cohort, D-dimer value was not specific enough to predict thrombotic complications. Adolescence and previous thrombotic risk factors may be considered when initiating anticoagulant prophylaxis on children with SARS-CoV-2 disease (COVID-19).

17 July 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ECElvira Cobo-Vázquez
Elvira Cobo-Vázquez
DADavid Aguilera-Alonso
David Aguilera-Alonso
DGDavid Grandioso-Vas
David Grandioso-Vas
AGAnna Gamell
Anna Gamell
VRVictoria Rello-Saltor
Victoria Rello-Saltor
OGon behalf PedGAS-net Working Group
on behalf PedGAS-net Working Group
A global surge in pediatric invasive group A streptococcal infection (iGAS) was reported after autumn 2022. This study analyzed the epidemiology and severity of iGAS in Spain, comparing two periods; P1: pre-outbreak (January 2019-September 2022) versus P2: outbreak (October 2022-July 2023). Children ≤16 years with iGAS enrolled in the Spanish PedGAS-net (2019-2023), were included. Bacterial isolates were analyzed for emm typing, antibiotic susceptibility, and whole genome sequencing. Multivariate analysis identified risk factors for PICU admission and mortality. 558 cases were included; 307 (55.1%) were male, with a median age of 43.9 months (IQR:19.3-84.1). There were significantly more iGAS in P2 (35.7 vs. 4.5 cases/month, P < 0.001), with higher PICU admissions (51.3% vs. 30.8%, P < 0.001). Pneumonia was the most common syndrome (32.3%), with pleural effusion in 58.3%. Of the 130 samples available for emm-typing, the most frequent were emm1 (56.1%) and emm12 (27.1%). 245 (43.9%) required PICU admission. Factors associated with PICU were streptococcal toxic shock syndrome (STSS), pneumonia, necrotizing fasciitis, acute kidney failure, and previous consultation before diagnosis. The emm1 (especially M1UK) increased PICU risk. 11 children (2.0%) died. STSS, sepsis, and central nervous system infection were associated with mortality. In Spain, pediatric iGAS cases sharply increased during 2022-2023, with a remarkable increase in severity. Epidemiological surveillance of iGAS remains crucial.